<DOC>
	<DOCNO>NCT00959647</DOCNO>
	<brief_summary>This multicenter , open-label extension study . Patients receive vismodegib ( GDC-0449 ) Genentech-sponsored study complete parent study continue receive vismodegib time parent study close eligible continued treatment protocol .</brief_summary>
	<brief_title>A Study Vismodegib ( GDC-0449 ) Patients Treated With Vismodegib Previous Genentech-sponsored Phase I II Cancer Study</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>This study enrol participant take part previous study vismodegib conduct Genentech . Completed vismodegib treatment within 24 week Genentechsponsored parent study continue receive vismodegib time Genentechsponsored parent study close . Expectation investigator participant may continue benefit additional vismodegib treatment . Intervening antitumor therapy specify parent study ( ie , nonprotocolspecified chemotherapy , target therapy , radiation therapy , photodynamic therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hedgehog pathway inhibitor</keyword>
</DOC>